The Role of Minimal Residual Disease in Chronic Lymphocytic Leukemia

被引：0

作者：

Al-Sawaf, Othman ^{[1
,2
,3
,4
,5
]}

Hallek, Michael ^{[1
,2
,3
]}

Fischer, Kirsten ^{[1
,2
,3
]}

机构：

[1] Univ Cologne, Fac Med, Cologne, Germany

[2] Univ Cologne, Univ Hosp Cologne, Dept Internal Med 1, Cologne, Germany

[3] Ctr Integrated Oncol Aachen Bonn Cologne Dusseldo, German CLL Study Grp, Aachen, Germany

[4] Francis Crick Inst, London, England

[5] UCL, UCL Canc Inst, London, England

来源：

CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY | 2022年 / 20卷 / 02期

关键词：

Chemoimmunotherapy; chronic lymphocytic leukemia (CLL); fixed-duration therapy; minimal residual disease (MRD); targeted agents; OPEN-LABEL; FLOW-CYTOMETRY; FOLLOW-UP; INDEPENDENT PREDICTOR; CELL TRANSPLANTATION; CLL; RITUXIMAB; VENETOCLAX; FLUDARABINE; CHEMOIMMUNOTHERAPY;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Minimal residual disease (MRD) has evolved as a sensitive and highly prognostic surrogate parameter of response to therapy in chronic lymphocytic leukemia (CLL). Multiple methods have been established to measure and quantify MRD during and after therapy. The improved sensitivity of MRD measurements has made it possible to develop limited-duration therapies, first with chemotherapy and chemoimmunotherapy and now also with combined targeted therapy. Moreover, concepts to integrate MRD information beyond prognostication-to guide duration of treatment and determine sensitivity-are at present being explored in prospective trials. In this review, we summarize currently available methods of MRD detection, provide recent MRD data and outcomes from clinical trials in CLL, and discuss open questions and future approaches for MRD within and outside clinical trials.

引用

页码：97 / 103

页数：7

共 50 条

[21] Should Undetectable Minimal Residual Disease Be the Goal of Chronic Lymphocytic Leukemia Therapy?
Al-Sawaf, Othman
Seymour, John F.
Kater, Arnon P.
Fischer, Kirsten
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2021, 35 (04) : 775 - 791
[22] Alemtuzumab until minimal residual disease for chronic lymphocytic leukemia: Is it a new standard?
Goodman, M
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (28) : 7240 - 7241
[23] Eradicating Minimal Residual Disease in Chronic Lymphocytic Leukemia: Should This Be the Goal of Treatment?
Varghese, Abraham M.
Rawstron, Andy C.
Hillmen, Peter
CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 2010, 5 (01) : 35 - 44
[24] THE MEANING OF THE MINIMAL RESIDUAL DISEASE IN CHRONIC LYMPHOCYTIC LEUKEMIA IN THE ERA OF TARGETED DRUGS
Kuvshinov, A. Yu
Voloshin, S. V.
Martynkevich, I. S.
Kleina, E., V
Chechetkin, A., V
GEMATOLOGIYA I TRANSFUZIOLOGIYA, 2016, 61 (04): : 190 - 196
[25] Minimal residual disease in chronic lymphocytic leukaemia
Garcia Vela, Jose Antonio
Garcia Marco, Jose Antonio
MEDICINA CLINICA, 2018, 150 (04): : 144 - 149
[26] Studies of minimal residual disease in acute lymphocytic leukemia
Stock, W
Estrov, Z
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2000, 14 (06) : 1289 - +
[27] Challenging the Value of Minimal Residual Disease in Predicting Outcome of Patients With Chronic Lymphocytic Leukemia
Kipps, Thomas J.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (21) : 3676 - +
[28] Measurable residual disease in chronic lymphocytic leukemia
Benintende, Giulia
Pozzo, Federico
Innocenti, Idanna
Autore, Francesco
Fresa, Alberto
D'Arena, Giovanni
Gattei, Valter
Lurenti, Luca
FRONTIERS IN ONCOLOGY, 2023, 13
[29] Alemtuzumab until minimal residual disease for chronic lymphocytic leukemia: Is it a new standard? Reply
Moreton, P
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (28) : 7241 - 7242
[30] Minimal Residual Disease Provides Treatment Focus for Next Chronic Lymphocytic Leukemia Advances
Wierda, William G.
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (31) : 3722 - +

← 1 2 3 4 5 →